Ann: Application for quotation of securities - ATX, page-8

IN THE NEWS | US-based Verastem has released data from their Phase 2 clinical trial evaluating a combination therapy, involving FAK-inhibitor defactinib, in the treatment of low grade serous ovarian cancer (LGSOC) - prompting a share price jump

In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.
Safety and tolerability continued to be favorable and consistent with previously reported data. These data, which will be presented at the American Society of Clinical Oncology Annual Meeting, build on the Breakthrough Therapy Designation granted by the U.S. Food and Drug Administration (FDA) for the combination in recurrent LGSOC.

This sounds familia ...

Avutometinib ... is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply.


And importantly ...

Tumour shrinkage in 86% (25/29) of evaluable patients

.